Please try another search
Dimension Therapeutics, Inc. develops a gene therapy platform that focuses on discovering and developing therapeutic products for people living with rare and metabolic diseases associated with the liver. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver FIX gene expression in patients with hemophilia B; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Its pipeline programs also comprise DTX301, a gene therapy product candidate for the treatment of ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of glycogen storage disease type Ia; DTX501, gene therapy program for the treatment of patients with PKU; DTX701, a gene therapy program for the treatment of Wilson disease; and DTX601, a gene therapy program for the treatment of citrullinemia type I. Dimension Therapeutics, Inc. was founded in 2013 and is based in Cambridge, Massachusetts. Dimension Therapeutics, Inc. operates as a subsidiary of Ultragenyx Pharmaceutical Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review